A Phase 1 Study of ARN-6039

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 16, 2016

Primary Completion Date

October 6, 2016

Study Completion Date

February 28, 2017

Conditions
Multiple Sclerosis
Interventions
DRUG

ARN-6039

Ascending doses per Cohort

OTHER

Placebo

Placebo to match ARN-6039

Sponsors
All Listed Sponsors
collaborator

Worldwide Clinical Trials

OTHER

lead

Arrien Pharmaceuticals

INDUSTRY